Artms Closes US$19M Series A Financing

Artms, Inc., a Vancouver, British Columbia, Canada-based developer of technology that transforms the production of diagnostic imaging isotopes, raised US$19m in Series A financing.

The round was led by Deerfield Management Company with participation from GHS Fund (Quark Venture LP and GF Securities).

The company intends to use the funds to continue to collaborate with industry partners with the aim of developing cyclotron produced 68Ga-based diagnostic and to expand the commercialization of the QISTM for the production of additional critical medical isotopes.

Led by Charles S. Conroy, Chief Executive Officer, Artms provides the QUANTM Irradiation SystemTM (QISTM), which enables decentralized, and local production of important medical isotopes including gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu).

The technology utilizes locally-based medical cyclotrons, empowering the user to control their supply chain and produce high volumes of innovative high-quality radiopharmaceutical products.

Source, FinSMEs, May 20, 2020

***

This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.

Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.

Olio Raises $2.5 Million to Grow Healthcare Collaboration Technology

CARMEL, Ind., March 12, 2019 /PRNewswire/ -- Olio, the only collaboration platform that digitally connects hospital and physician teams with post-acute providers around the patient's healthcare episode type, announced today that it has raised $2.5 million in seed funding. The oversubscribed round was concentrated in strategic seed investors who explicitly understand the complexity of the healthcare environment, the challenges ahead within the industry, and the challenge that Olio addresses.

Olio's secure platform enables greater collaboration between acute and post-acute healthcare providers, so patients receive more coordinated care. The platform gives hospitals, physicians, and their teams clear and immediate insights into their patients' conditions across the post-acute environment (skilled nursing facilities, home health agencies, and outpatient physical therapy) to improve clinical outcomes and lower costs. The company intends to use the round of funding to further scale the technology, expand nationally, innovate with its clients, and grow its engineering, marketing, and customer success teams. Olio is on pace to add approximately 80 jobs in Central Indiana by 2020. Olio is a recipient of the Indiana Venture Capital Investment Tax Credit by the State's Economic Development Corp, designed to support fast-growing Indiana companies.

"With Olio, health systems are able to improve clinical outcomes for their patients, and improve financial performance in value-based healthcare," said Ben Forrest, founder and CEO of Olio. "With this funding, we'll further advance our technology that is enabling health systems and physicians to provide the highest quality of care as patients transition to care facilities outside of the hospital's walls."

"Olio is helping solve the communication gap that exists between physicians, hospitals, and post-acute healthcare providers," said P. Jamieson Kay, MD, Orthopedic Surgeon and President, Central Indiana Orthopedics. "Olio enables Central Indiana Orthopedics to collaborate more effectively with caregivers across the patient's entire episode of care. As a result, our patients receive the highest-level of coordinated care and Central Indiana Orthopedics can efficiently manage our patient population, their experience, and the overall cost of care."

"The most successful startups combine industry expertise with an exceptional digital experience," said Mike Reynolds, CEO of Innovatemap Ventures, Olio investor and advisor. "Olio's timing is ideal to seize this market opportunity and fill a critical need by connecting a fragmented industry. I'm excited to see what successes are in store for them in 2019."

Olio has partnered with progressive Midwest healthcare providers, who are engaged in value-based arrangements including Medicare Advantage, Managed Medicaid, BCPI-A, ACOs, and other risk-bearing healthcare reimbursement models. Olio is in the process of implementation with additional health systems, physicians, and post-acute providers committed to technology-enabled solutions to improve patient care and experience across the care continuum.

About Olio

Olio enables greater collaboration between acute and post-acute healthcare providers, so patients receive more coordinated care. Physicians receive immediate visibility into patient care beyond the hospital. Care coordinators gain access to specialty specific progress data on patients. Hospital systems improve financial performance as a result of increased clinical effectiveness. For more information, visit www.olio.health.



SOURCE Olio, Press Release, March 12, 2019